CAS 1326232-46-5
:Anifrolumab
Description:
Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, specifically designed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). It is classified as a biologic drug and functions by inhibiting the activity of type I interferons, which are involved in the inflammatory response and immune regulation. Anifrolumab is administered via subcutaneous injection and has been shown to reduce disease activity in patients with SLE, leading to improvements in various clinical manifestations. The drug's mechanism of action involves modulating the immune system, thereby decreasing the production of pro-inflammatory cytokines and autoantibodies. Clinical trials have demonstrated its efficacy and safety profile, although potential side effects may include increased risk of infections and infusion-related reactions. As a biologic, anifrolumab is subject to specific storage and handling requirements to maintain its stability and effectiveness. Overall, it represents a targeted therapeutic approach in the management of complex autoimmune conditions.
Formula:Unspecified
Synonyms:- Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546 κ-chain, dimer
- MEDI 546
- Anifrolumab
- Immunoglobulin G1, anti-(human interferon α/β receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546 κ-chain, dimer
- Anifrolumab-fnia
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
Anifrolumab
CAS:Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity ofPurity:> 95% - > 95%Color and Shape:LiquidMolecular weight:144.92 kDaAnifrolumab
CAS:<p>Monoclonal antibody targeting Interferon α/β receptor; used to treat systemic lupus erythematosus</p>
